FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.
Elaine Chang(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Jessica E. Hawley(Columbia University Irving Medical Center), Meredith M. Regan(Dana-Farber Cancer Institute), Amna Ibrahim(Beni-Suef University), Brian I. Rini(Vanderbilt University Medical Center), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Toni K. Choueiri(Harvard University), Michael B. Atkins(Georgetown University), Paul G. Kluetz(United States Food and Drug Administration), Marc R. Theoret(United States Food and Drug Administration), Thomas Gwise(United States Food and Drug Administration), Laura L. Fernandes(United States Food and Drug Administration), Chana Weinstock(United States Food and Drug Administration), Yutao Gong(Center for Drug Evaluation and Research), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k